Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging

Oncogene volume 20, pages 295–302 (2001)Cite this article

Abstract

The Runx2 (Cbfa1, Pebp2αA, Aml3) gene was previously identified as a frequent target for transcriptional activation by proviral insertion in T-cell lymphomas of CD2-MYC transgenic mice. We have recently shown that over-expression of the full-length, most highly expressed Runx2 isoform in the thymus perturbs T-cell development, leads to development of spontaneous lymphomas at low frequency and is strongly synergistic with Myc. To gain further insight into the relationship of Runx2 to other lymphomagenic pathways, we tested the effect of combining the CD2-Runx2 transgene either with a Pim1 transgene (Eμ-Pim1) or with the p53 null genotype, as each of these displays independent synergy with Myc. In both cases we observed synergistic tumour development. However, Runx2 appeared to have a dominant effect on the tumour phenotype in each case, with most tumours conforming to the CD3+, CD8+, CD4+/− phenotype seen in CD2-Runx2 mice. Neonatal infection of CD2-Runx2 mice with Moloney murine leukaemia virus (Moloney MLV) also led to a dramatic acceleration of tumour onset. Analysis of known Moloney MLV target genes in these lymphomas showed a high frequency of rearrangement at c-Myc or N-Myc (82%), and a significant number at Pim1 or Pim2 (23%), and at Pal1/Gfi1 (18%). These results indicate that Runx2 makes a distinct contribution to T-cell lymphoma development which does not coincide with any of the oncogene complementation groups previously identified by retroviral tagging.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Adams JM, Harris AW, Pinkert LM, Corcoran LM, Alexander WS, Cory S, Palmiter RD and Brinster RL. . 1985 Nature 318: 533–538.

  • Alkema MJ, Jacobs H, van Lohuizen M and Berns A. . 1997 Oncogene 15: 899–910.

  • Baxter EW, Blyth K, Donehower LA, Cameron ER, Onions DE and Neil JC. . 1996 J. Virol. 70: 2095–2100.

  • Berns A, Mikkers H, Krimpenfort P, Allen J, Scheijen B and Jonkers J. . 1999 Cancer Res. 59: 1773s–1777s.

  • Blyth K, Terry A, O'Hara M, Baxter EW, Campbell M, Stewart M, Donehower L, Onions DE, Neil JC and Cameron ER. . 1995 Oncogene 10: 1717–1723.

  • Blyth K. . 1996 Ph.D Thesis, University of Glasgow Veterinary School. A transgenic model to study the role of oncogenes and tumour suppressor genes in T cell lymphoma.

  • Blyth K, Stewart M, Bell M, James C, Evan GI, Neil J and Cameron ER. . 2000 Oncogene 19: 773–782.

  • Breuer ML, Cuypers HT and Berns A. . 1989 EMBO J. 8: 743–748.

  • Clark SS, Chen E, Fizzotti M, Witte ON and Malkovska V. . 1993 J. Virol. 67: 6033–6046.

  • Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, van Wezenbeek P, Melief C and Berns A. . 1984 Cell 37: 141–150.

  • DePinho R and Jacks T (eds.) . 1999 Oncogene Reviews Mouse Models of Cancer. Stockton Press: Hampshire RG21 6XS.

  • Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS and Bradley A. . 1992 Nature 356: 215–221.

  • Ducy P, Zhang R, Geoffroy V, Ridall AL and Karsenty G. . 1997 Cell 89: 747–754.

  • Gilks CB, Bear SE, Grimes HL and Tsichlis PN. . 1993 Mol. Cell Biol. 13: 1759–1768.

  • Girard L, Hanna Z, Beaulieu N, Hoemann CD, Simard C, Kozak CA and Jolicoeur P. . 1996 Genes Dev. 10: 1930–1944.

  • Harvey M, McArthur MJ, Montgomery CA, Bradley A and Donehower LA. . 1993 FASEB J. 7: 938–943.

  • Kania MA, Bonner AS, Duffy JB and Gergen JP. . 1990 Genes Dev. 4: 1701–1713.

  • Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S and Kishimoto T. . 1997 Cell 89: 755–764.

  • Lazo PA, KleinSanto AJP and Tsichlis PN. . 1990 J. Virol. 64: 3948–3959.

  • Leverson JD, Koskinen PJ, Orrico FC, Rainio EM, Jalkanen KJ, Dash AB, Eisenman RN and Ness SA. . 1998 Mol. Cell 2: 417–425.

  • Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada D, Nakamura T, Shaughnessy JD, Jenkins NA and Copeland NG. . 1999 Nat. Genet. 23: 348–353.

  • Liao X, Buchberg AM, Jenkins NA and Copeland NG. . 1995 J. Virol. 69: 7132–7137.

  • Lilly M and Kraft A. . 1997 Cancer Res. 57: 5248–5355.

  • Lilly M, Sandholm J, Cooper JJ, Koskinen PJ and Kraft A. . 1999 Oncogene 18: 4022–4031.

  • Look T. . 1997 Science 278: 1059–1064.

  • Meyers S, Lenny N, Sun W and Hiebert SW. . 1996 Oncogene 13: 303–312.

  • Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, Yokoyama K, Soeda E and Ohki M. . 1995 Nucleic Acids Res. 23: 2762–2769.

  • Mochizuki T, Kitanaka C, Noguchi K, Sugiyama A, Kagaya S, Chi S, Asai A and Kuchino Y. . 1997 Oncogene 15: 1471–1480.

  • Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A and Kuchino Y. . 1999 J. Biol. Chem. 274: 18659–18666.

  • Nesbit CE, Tersak JM and Prochownik EV. . 1999 Oncogene 18: 3004–3016.

  • North T, Gu TL, Stacy T, Wang Q, Howard L, Binder M, Marin-Padilla M and Speck NA. . 1999 Development 126: 2563–2575.

  • Ogawa E, Maruyama M, Kagoshima H, Inuzuka M, Lu J, Satake M, Shigesada K and Ito Y. . 1993 Proc. Natl. Acad. Sci. USA 90: 6859–6863.

  • Okuda T, van Deursen J, Hiebert SW, Grosveld G and Downing JR. . 1996 Cell 84: 321–330.

  • Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GWH, Beddington RSP, Mundlos S, Olsen BR, Selby PB and Owen MJ. . 1997 Cell 89: 765–771.

  • Prendergast GC. . 1999 Oncogene 18: 2967–2987.

  • Poirier Y, Kozak C and Jolicoeur P. . 1988 J. Virol. 62: 3985–3992.

  • Satake M, Nomura S, Yamagachi-Iwai Y, Takahama Y, Hashimoto Y, Niki M, Kitamura Y and Ito Y. . 1995 Mol. Cell. Biol. 15: 1662–1670.

  • Scheijen B, Jonkers J, Acton D and Berns A. . 1997 J. Virol. 71: 9–16.

  • Schmidt T, Karsunky H, Gau E, Zevnik B, Elsasser HP and Moroy T. . 1998 Oncogene 17: 2661–2667.

  • Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M and Hirano T. . 1999 Immunity 11: 709–719.

  • Stewart MA, Cameron E, Campbell M, McFarlane R, Toth S, Lang K, Onions D & Neil JC. . 1993 Int. J. Cancer 53: 1023–1030.

  • Stewart MA, Terry A, O'Hara M, Cameron ER, Onions DE and Neil JC. . 1996 J. Gen Virol. 77: 443–446.

  • Stewart M, Terry A, O'Hara M, Blyth K, Baxter E, Cameron E, Onions D and Neil JC. . 1997 Proc. Natl. Acad. Sci. USA 94: 8646–8651.

  • Vaillant F, Blyth K, Terry A, Bell M, Cameron ER, Neil J and Stewart M. . 1999 Oncogene 18: 7124–7134.

  • van der Lugt NMT, Domen J, Verhoeven E, Linders K, van der Gulden H, Allen J and Berns A. . 1995 EMBO J. 14: 2536–2544.

  • van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T and Berns A. . 1989 Cell 56: 673–682.

  • van Lohuizen M, Verbeek S, Scheijen B, Wientjens E, van der Gulden H and Berns A. . 1991 Cell 65: 737–752.

  • Vijaya S, Steffen DL, Kozak C and Robinson HL. . 1987 J. Virol. 61: 1164–1170.

  • Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe AH and Speck NA. . 1996 Proc. Natl. Acad. Sci. USA 93: 3444–3449.

  • Zaiman AL, Lewis AF, Crute BE, Speck NA and Lenz J. . 1995 J. Virol. 69: 2898–2906.

Download references

Acknowledgements

We are grateful to Monica Cunningham for invaluable technical assistance. This work was funded by the Cancer Research Campaign and the Leukaemia Research Fund of Great Britain.

Author information

Authors and Affiliations

  1. Molecular Oncology Laboratory, University of Glasgow Veterinary School, Bearsden, Glasgow, G61 1QH, UK

    Karen Blyth, Anne Terry, Nancy Mackay, François Vaillant, Margaret Bell, Ewan R Cameron, James C Neil & Monica Stewart

Authors
  1. Karen Blyth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Terry
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nancy Mackay
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. François Vaillant
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Margaret Bell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ewan R Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. James C Neil
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Monica Stewart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Blyth, K., Terry, A., Mackay, N. et al. Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene 20, 295–302 (2001). https://doi.org/10.1038/sj.onc.1204090

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204090

Keywords

This article is cited by

Search

Advanced search

Quick links